North America Benign Prostatic Hyperplasia Treatment Market Size and Share Report 2026-2034

North America Benign Prostatic Hyperplasia Treatment Market Size

North America Benign Prostatic Hyperplasia Treatment Market size is projected at USD 4,472.78 million in 2026 and is expected to hit USD 7,014.75 million by 2034 with a CAGR of 5.8%. The market stood at USD 4,228.13 million in 2025, implying an absolute forecast-period addition of approximately USD 2,541.97 million. Assessment of treatment categories, country-level performance, patient profiles, distribution channels, technology adoption, and the competitive landscape is essential for identifying commercially attractive areas through 2034.

Key Takeaways

The United States dominates the country landscape with approximately77.09%of 2026 revenue, representing USD3,448.06 million, and is forecast to reach USD5,413.28 millionby 2034 at5.80% CAGR.
Canada accounts for approximately22.91%in 2026, with revenue increasing from USD1,024.72 millionto USD1,601.47 millionby 2034 at5.74% CAGR.
Pharmacological treatment is the dominant treatment category, accounting for approximately40.78%of the 2026 treatment-type total, at USD1,824.21 million.
Surgical treatment is the fastest-growing supplied treatment category at5.86% CAGR, increasing from USD1,197.30 millionin 2026 to USD1,888.24 millionin 2034.
Minimally invasive procedures represent approximately19.12%of 2026 treatment revenue and are forecast to increase from USD855.35 millionto USD1,315.69 millionby 2034.

The benign prostatic hyperplasia treatment industry encompasses pharmacological therapies, conventional surgery, minimally invasive procedures, and conservative approaches used to manage lower urinary tract symptoms associated with non-cancerous prostate enlargement. Based on supplied 2026 values, pharmacological treatments contribute 40.78%, surgical treatments 26.77%, minimally invasive procedures 19.12%, and other treatments 13.33%. Country-level revenue is concentrated in the United States at USD 3,448.06 million, compared with USD 1,024.72 million in Canada. The supplied dataset does not quantify physical North American production volumes; consequently, revenue values are used as the primary quantitative measure rather than introducing unsupported production estimates.

Source: Company Publications, Primary Interviews, and skymarketinsights Analysis

Explore more data points, trends and opportunities Download Free Sample Report

North America Benign Prostatic Hyperplasia Treatment Market Trends

Shift Toward Minimally Invasive, Function-Preserving Therapies

Technology development is increasingly focused on bridging the clinical gap between long-term medication and conventional procedures such as TURP. A 2024 systematic review evaluating newer interventions covered 32 studies, including 10 randomized controlled trials, 22 prospective observational cohorts, and approximately 2,400 patients, with a median patient age of 66 years and median prostate volume of 51.9 mL. These figures illustrate the expanding clinical evidence base behind UroLift, Rezūm, aquablation, PAE, and related technologies.

Technology adoption is being influenced by shorter recovery objectives and preservation of sexual function. Canada's Drug Agency assessed 4 minimally invasive approaches UroLift, Rezūm, PAE, and aquablation and noted that patients may accept somewhat lower symptom relief in exchange for fewer adverse events and reduced sexual-function risks. The FDA identifies UroLift for men aged 50 years and above, while Rezūm delivers controlled water-vapor energy in 9-second doses, demonstrating how procedure-specific technologies are broadening treatment pathways.

North America Benign Prostatic Hyperplasia Treatment Market Drivers

Aging Patient Population and Broader Treatment Choice

Increasing treatment requirements among older men support sustained therapeutic utilization across medications and procedures. Clinical research involving newer surgical interventions reported a median patient age of 66 years, median prostate volume of 51.9 mL, and median International Prostate Symptom Score of 22 across approximately 2,400 participants. At the same time, treatment pathways span at least 4 major approaches pharmacotherapy, conventional surgery, minimally invasive intervention, and conservative management supporting demand across hospitals, clinics, ambulatory centers, and specialist practices.

North America Benign Prostatic Hyperplasia Treatment Market Restraints

Durability, Re-intervention and Procedure Selection Concerns

Clinical uncertainty regarding long-term durability can restrain migration from established therapies toward newer procedures. A systematic review analyzed 32 studies, but only 10 were randomized controlled trials, versus 22 prospective observational cohorts, highlighting differences in evidence quality across technologies. Canada's assessment of 4 minimally invasive technologies further noted that symptom relief may be lower than with conventional TURP, despite advantages involving recovery and adverse-event profiles. These trade-offs make prostate size, symptom severity, age, retreatment risk, and sexual-function priorities important purchasing and treatment-selection variables.

North America Benign Prostatic Hyperplasia Treatment Market Opportunities

Expansion of Office-Based and Minimally Invasive Intervention

Innovation creates opportunities to move suitable patients away from prolonged medication or more invasive surgery. FDA-cleared Rezūm technology administers water vapor through controlled 9-second treatments, while UroLift is indicated for patients aged 50+ years. More recently, the Zenflow Spring Implant received an indication covering prostate sizes of 25–80 cc and prostatic urethral lengths of 25–45 mm, expanding the range of device-based treatment architectures available to clinicians.

Challenges in North America Benign Prostatic Hyperplasia Treatment Market

Balancing Clinical Outcomes, Recovery and Patient Preferences

Providers must match multiple technologies to heterogeneous patient anatomy and expectations. Evidence comparing newer interventions includes approximately 2,400 patients, a median prostate size of 51.9 mL, and 32 studies, yet durability remains an important differentiator. Newer implants may also have defined anatomical windows for example, the Zenflow Spring indication covers 25–80 cc prostates and 25–45 mm prostatic urethral lengths requiring careful patient selection rather than universal procedural adoption.

Report Scope

Report Metric	Details
Market Size in 2025	USD 4228.13 Million
Market Size in 2026	USD 4472.78 Million
Market Size in 2034	USD 7014.75 Million
CAGR	5.8% (2026-2034)
Base Year for Estimation	2025
Historical Data	2022-2024
Forecast Period	2026-2034
Report Coverage	Revenue Forecast, Competitive Landscape, Supply Chain Disruption, Growth Factors, Environment & Regulatory Landscape and Trends

Explore more data points, trends and opportunities Download Free Sample Report

North America Benign Prostatic Hyperplasia Treatment Market Segmentation

Treatment segmentation indicates clear revenue concentration in pharmacological management. In 2026, pharmacological treatment accounts for approximately 40.78%, surgical treatment 26.77%, minimally invasive procedures 19.12%, and other treatments 13.33% of the supplied treatment-type total of USD 4,473.00 million.

By Treatment Type

Pharmacological treatment is the largest category, rising from USD 1,824.21 million in 2026 to USD 2,874.76 million by 2034 at 5.85% CAGR. It includes alpha-blockers such as tamsulosin, silodosin, alfuzosin and doxazosin; 5-ARIs including dutasteride and finasteride; combination therapy; PDE5 inhibitors; and other drugs.

Surgical treatment is the fastest-growing supplied category at 5.86% CAGR, advancing from USD 1,197.30 million to USD 1,888.24 million. Minimally invasive procedures increase from USD 855.35 million to USD 1,315.69 million at 5.53% CAGR, while other treatments expand from USD 596.14 million to USD 939.45 million at 5.85% CAGR.

By End Use

Hospitals remain central to TURP, prostatectomy, laser procedures, and complex cases, while clinics and specialty urology centers increasingly support diagnostic management and selected minimally invasive interventions. The supplied dataset assigns 4 end-use categories and 4 principal treatment groups but does not provide end-use revenue or CAGR, so unsupported numerical allocations are not introduced.

Ambulatory surgical centers provide another procedural setting as shorter-stay technologies expand. Across the broader clinical evidence base, newer surgical interventions have been assessed in 32 studies and approximately 2,400 patients, supporting continuing evaluation of outpatient-compatible approaches.

By Patient Age Group

The segmentation covers 3 cohorts: below 50 years, 50–60 years, and above 60 years. Older patients represent a particularly important treatment population; evidence on newer interventions reports a median age of 66 years, while UroLift's FDA indication begins at age 50.

Treatment intensity generally progresses from surveillance and medication toward procedural intervention according to symptoms and anatomy. The supplied tables do not provide age-group revenue or CAGR; therefore, no fabricated percentage allocation is applied to the 3 age cohorts.

By Distribution Channel

Distribution comprises 3 channels: hospital pharmacy, retail pharmacy, and online pharmacy. Prescription therapies including alpha-blockers, 5-ARIs, PDE5 inhibitors, and combination regimens create recurring pharmaceutical demand, whereas procedural devices are principally deployed through institutional channels.

Hospital and retail channels remain relevant to ongoing medication management, while digital fulfillment increases accessibility for eligible prescriptions. Because the supplied numerical tables contain 4 treatment categories but no distribution-channel revenue or CAGR, quantitative channel shares are intentionally not estimated.

North America Benign Prostatic Hyperplasia Treatment Market Segmentations

By Treatment Type

Pharmacological treatment
- Alpha-blockers
- 5-alpha reductase inhibitors (5-ARI)
- Combination therapy
- Phosphodiesterase-5 inhibitors (pde5 inhibitors)
- Herbal and other drugs
Surgical treatment
- Transurethral resection of the prostate (TURP)
- Transurethral incision of the prostate (TUIP)
- Open prostatectomy
- Laser therapy
Minimally invasive procedures
- Urolift system
- RezÅ«m water vapour therapy
- Prostatic artery embolisation
- Microwave thermotherapy
- Transurethral needle ablation (TUNA)
Other treatments
- Lifestyle modifications
- Watchful waiting / active surveillance

By End Use

Hospitals
Clinics
Ambulatory surgical centres
Specialty urology centers

By Patient Age Group

Below 50 years
50–60 years
Above 60 years

By Distribution Channel

Hospital pharmacy
Retail pharmacy
Online pharmacy

North America Benign Prostatic Hyperplasia Treatment Market Counties Outlook

U.S.

The United States represents approximately 77.09% of North American revenue in 2026, with USD 3,448.06 million, compared with USD 3,259.04 million in 2025. Revenue is projected to reach USD 5,413.28 million by 2034 at 5.80% CAGR, an absolute increase of USD 1,965.22 million from 2026.

The country benefits from a broad treatment ecosystem spanning pharmaceuticals, TURP, laser therapies, UroLift, Rezūm, PAE, and newer devices. The supplied dataset does not disclose U.S. physical production or country-specific treatment splits; therefore, the 77.09% revenue contribution is used as the principal country indicator.

Canada

Canada contributes approximately 22.91% of 2026 regional revenue, reaching USD 1,024.72 million, up from USD 969.09 million in 2025. The country is forecast to reach USD 1,601.47 million by 2034 at 5.74% CAGR, adding approximately USD 576.75 million over 2026–2034.

Canadian technology assessment has specifically examined 4 minimally invasive options UroLift, Rezūm, PAE, and aquablation alongside conventional treatment pathways. Physical production and country-level sector splits are not supplied, so no unsupported volume assumptions are incorporated.

Regional Growth Insights Download Free Sample

Top players in North American benign prostatic hyperplasia treatment market

Boston Scientific Corporation
Teleflex Incorporated
Olympus Corporation
PROCEPT BioRobotics Corporation
KARL STORZ SE & Co. KG
Richard Wolf GmbH
Cook Medical
Medtronic plc
Urotronic, Inc.
Zenflow, Inc.
GlaxoSmithKline plc
Viatris Inc.
Sanofi S.A.
Astellas Pharma Inc.
Eli Lilly and Company

Top Two Companies

Boston Scientific Corporation:Boston Scientific holds a prominent competitive position through the Rezūm water-vapor platform. The FDA recorded aJune 11, 2025substantially-equivalent decision for the Rezūm System under 510(k) K250584, while the technology delivers vapor in controlled9-seconddoses. A verified company-specific North American percentage revenue share is not contained in the supplied dataset or cited regulatory evidence; therefore, assigning an unsupported percentage would conflict with the mandatory-data requirement.
Teleflex Incorporated:Teleflex is strongly positioned in minimally invasive BPH therapy through the UroLift System. FDA information identifies UroLift as a Class II implantable transprostatic tissue retractor indicated for men aged50+, while 2024 comparative research included head-to-head evaluation against tamsulosin and Rezūm. No verified company-specific percentage revenue share was supplied, so competitive positioning is presented without fabricating a market-share percentage.

Recent Developments in North America Benign Prostatic Hyperplasia Treatment Market

2026: FDA information showed approval of the Zenflow Spring Implant for obstructive BPH symptoms in men with prostate sizes of 25–80 cc and prostatic urethral lengths of 25–45 mm.
2025: Boston Scientific's Rezūm System received an FDA 510(k) substantially equivalent decision on June 11, 2025, under submission K250584.
2025: Aqua Medical's RF Vapor Ablation System received an FDA 510(k) substantially equivalent decision on August 8, 2025, following an April 21, 2025, submission.
2025: A clinical review highlighted UroLift, Rezūm, and iTind as minimally invasive therapies designed to bridge pharmacological management and conventional endoscopic intervention.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year, and 2026–2034 as the forecast period, with 2022–2024 forming the historical framework. Supplied numerical tables were treated as the controlling source for market values, country contributions, treatment-category values, and CAGRs. Calculated percentages, including the U.S. 77.09%, Canada 22.91%, and pharmacological treatment 40.78% contributions in 2026, were derived directly from those supplied values. Secondary clinical and regulatory evidence was used only for technology, competitive, and development context. Where production volumes, end-use values, age-group revenue, distribution-channel values, or company percentage shares were unavailable, figures were not fabricated or substituted with unrelated estimates.

Frequently Asked Questions

What is the North America Benign Prostatic Hyperplasia Treatment Market size in 2026?

The North America Benign Prostatic Hyperplasia Treatment Market is projected to reach USD 4,472.78 million in 2026.

What is the forecast size of the North America Benign Prostatic Hyperplasia Treatment Market by 2034?

The North America Benign Prostatic Hyperplasia Treatment Market is expected to reach USD 7,014.75 million by 2034.

What is the CAGR of the North America Benign Prostatic Hyperplasia Treatment Market from 2026 to 2034?

The North America Benign Prostatic Hyperplasia Treatment Market is projected to grow at a CAGR of 5.8% from 2026 to 2034.

Which segment dominates the North America Benign Prostatic Hyperplasia Treatment Market?

Pharmacological treatment dominates the treatment category with USD 1,824.21 million in 2026, representing approximately 40.78% of treatment revenue. The United States dominates the country landscape with USD 3,448.06 million, accounting for approximately 77.09% of 2026 regional revenue.

Who are the top players in the North America Benign Prostatic Hyperplasia Treatment Market?

Author: Jenny Burkett

Senior Market Research Analyst | 8 Years Experience | Digital Therapeutics and Connected Medical Devices

Jenny specializes in digital therapeutics, remote monitoring devices and healthcare IT platforms. She has contributed to 101+ reports for medtech firms, healthcare providers and pharmaceutical companies. Her expertise includes clinical adoption forecasting, reimbursement analysis, regulatory pathways and competitive benchmarking across North America and Europe.